Landscape of transarterial chemoembolization represented interventional therapy for hepatocellular carcinoma.

World J Gastrointest Surg

Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China.

Published: December 2024


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

This article discusses the article written by Tan . Transarterial chemoembolization (TACE) is one of the main treatment methods for advanced hepatocellular carcinoma (HCC). There are other vascular interventional therapies, including drug-eluting bead TACE, transarterial radioembolization, and hepatic arterial infusion chemotherapy. TACE combined with anti-angiogenesis therapy may improve tumor control and prolong progression free survival. The combination therapy of TACE and immunotherapy may improve the clinical efficacy of HCC. In future research, more basic and clinical studies are needed to explore the immunogenic intervention therapy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650251PMC
http://dx.doi.org/10.4240/wjgs.v16.i12.3903DOI Listing

Publication Analysis

Top Keywords

transarterial chemoembolization
8
hepatocellular carcinoma
8
landscape transarterial
4
chemoembolization represented
4
represented interventional
4
therapy
4
interventional therapy
4
therapy hepatocellular
4
carcinoma article
4
article discusses
4

Similar Publications

Purpose: Recent advancements in medical technologies have made trans-arterial treatment of breast cancer feasible. Consequently, understanding the vascular anatomies of breast cancers and axillary lymph node metastases has become indispensable for sophisticated treatments. The aim of this study was to determine the vascular anatomy of the breast, which is crucial for trans-arterial chemoembolization in patients with breast cancer.

View Article and Find Full Text PDF

Antitumor Effects of Doxorubicin-Loaded Cellulose Nanoparticles in the Rabbit VX2 Liver Tumor Model.

Cardiovasc Intervent Radiol

September 2025

Department of Radiology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, 82, Gumi-ro 173Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea.

Purpose: To evaluate the preclinical efficacy and safety of transarterial chemoembolization (TACE) using doxorubicin-loaded biocompatible cellulose nanoparticles in a rabbit VX2 liver tumor model.

Materials And Methods: Following institutional animal care committee approval, 23 rabbits with VX2 liver tumors were randomized into three groups: Group A (n = 9) received doxorubicin-loaded cellulose nanoparticles with ethiodized oil; Group B (n = 9) received doxorubicin with ethiodized oil; and Group C (n = 5) served as untreated controls. Tumor size was monitored via ultrasound for 4 weeks, and serum liver enzymes (aspartate transaminase and alanine transaminase) were measured on days 1, 3, and 7 to assess hepatotoxicity.

View Article and Find Full Text PDF

Background: This network meta-analysis (NMA) aims to compare the relative efficacy of oral Chinese patent medicine combined with transarterial chemoembolization (TACE) for treating hepatocellular carcinoma (HCC).

Methods: Databases, including China National Knowledge Infrastructure, Wanfang, Weipu, PubMed, Embase, Web of Science, and Cochrane Central Register of Controlled Trials (CENTRAL), were accessed from inception to the present to collect randomized controlled trials of different oral Chinese patent medicines (OCPMs). Objective response rate, 1-year survival rate, lymphocytes, nausea and vomiting were used as efficacy or tolerability outcomes.

View Article and Find Full Text PDF

Purpose: Transarterial chemoembolization (TACE) may cause gut dysbiosis by increasing portal vein pressure. However, its association with clinical outcomes remains unknown. We hypothesized that gut microbiota composition and diversity are associated with treatment response and prognosis in patients with hepatocellular carcinoma (HCC) undergoing TACE.

View Article and Find Full Text PDF